bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma
Authors: Hollebecque Antoine , Salvagni Stefania , Plummer Ruth , Isambert Nicolas , Niccoli Patricia , Capdevila Jaume , Curigliano Giuseppe , Moreno Victor , Martin-Romano Patricia , Baudin Eric , Arias Marina , Mora Sheila , de Alvaro Juan , Di Martino Jorge , Parra-Palau Josep L. , Sánchez-Pérez Tania , Aronchik Ida , Filvaroff Ellen H. , Lamba Manisha , Nikolova Zariana , de Bono Johann S.
Published: April 2023

Supplementary Figure S1. Antitumor Activity of CC-90011 in SCLC Patient-Derived Xenografts (PDXs). The effects of CC-90011 on a human SCLC PDX (LXFS 1129) model implanted subcutaneously in female athymic nude mice (NMRI-Foxn1nu). Female mice (n = 8) bearing the SCLC tumors were dosed orally with either 1.5 or 5 mg/kg/day of CC-90011 for 60 consecutive days or 10 mL/kg 0.5% methyl cellulose vehicle as a control. SCLC, small cell lung cancer. Data cutoff: 28 January 2019.
Supplementary File from Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma
Authors: Daemen Anneleen , Cooper Jonathan E. , Myrta Szymon , Wongchenko Matthew J. , Lin Eva , Long Jason E. , Foreman Oded , Modrusan Zora , Tremayne Jarrod R. , de la Cruz Cecile C. , Merchant Mark , Martin Scott E. , Yan Yibing , Junttila Melissa R.
Published: April 2023

Supplementary Methods, Figure legends and Table legends
Figure S1 from A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers
Authors: Mathur Divya , Root Adam R. , Bugaj-Gaweda Bozena , Bisulco Stephanie , Tan Xingzhi , Fang Wei , Kearney Jessica C. , Lucas Justin , Guffroy Magali , Golas Jonathan , Rohde Cynthia M. , Stevens Chad , Kamperschroer Cris , Kelleher Kerry , Lawrence-Henderson Rosemary F. , Upeslacis Erik , Yao Johnny , Narula Jatin , LaVallie Edward R. , Fernandez Diane R. , Buetow Bernard S. , Rosfjord Edward , Bloom Laird , King Lindsay E. , Tchistiakova Lioudmila , Nguyen Anhco , Sapra Puja
Published: April 2023

GUCY2C expression in non-intestinal human tissues
Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
Authors: Wahdan-Alaswad Reema S. , Edgerton Susan M. , Salem Hiba , Kim Hyun Min , Tan Aik Choon , Finlay-Schultz Jessica , Wellberg Elizabeth A. , Sartorius Carol A. , Jacobsen Britta M. , Haugen Bryan R. , Liu Bolin , Thor Ann D.
Published: April 2023

Supplementary Methods and Figures
Supplementary Data from Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers
Authors: Wahdan-Alaswad Reema S. , Edgerton Susan M. , Salem Hiba , Kim Hyun Min , Tan Aik Choon , Finlay-Schultz Jessica , Wellberg Elizabeth A. , Sartorius Carol A. , Jacobsen Britta M. , Haugen Bryan R. , Liu Bolin , Thor Ann D.
Published: April 2023

Supplementary Tables S1, S2A, S2B, S2C, S3, S4, S5 and Supplementary Figures S1, S2, S3, S4, S5, S6, S7, and S8.
Supplementary Data from YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma
Authors: Vigneswaran Krishanthan , Boyd Nathaniel H. , Oh Se-Yeong , Lallani Shoeb , Boucher Andrew , Neill Stewart G. , Olson Jeffrey J. , Read Renee D.
Published: April 2023

Supplementary Figures and Tables
Supplementary Legend from Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Authors: Janku Filip , Zhang Halle Huihong , Pezeshki Abdulmohammad , Goel Sanjay , Murthy Ravi , Wang-Gillam Andrea , Shepard Dale R. , Helgason Thorunn , Masters Tyler , Hong David S. , Piha-Paul Sarina A. , Karp Daniel D. , Klang Mark , Huang Steven Y. , Sakamuri Divya , Raina Anjali , Torrisi Jean , Solomon Stephen B. , Weissfeld Alice , Trevino Ernest , DeCrescenzo Gary , Collins Amanda , Miller Maria , Salstrom Jennifer L. , Korn Ronald L. , Zhang Linping , Saha Saurabh , Leontovich Alexey A. , Tung David , Kreider Brent , Varterasian Mary , Khazaie Khashayarsha , Gounder Mrinal M.
Published: April 2023

Supplementary Legend
Supplementary Figure S4 from Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Authors: Estrada-Bernal Adriana , Le Anh T. , Doak Andrea E. , Tirunagaru Vijaya G. , Silva Shevan , Bull Matthew R. , Smaill Jeff B. , Patterson Adam V. , Kim Chul , Liu Stephen V. , Doebele Robert C.
Published: April 2023

Tarloxotinib (prodrug) is less effective against WT and mutant forms of EGFR and HER2.
Table S1 from Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Authors: Zhang Jiajia , Ji Zhicheng , Caushi Justina X. , El Asmar Margueritta , Anagnostou Valsamo , Cottrell Tricia R. , Chan Hok Yee , Suri Prerna , Guo Haidan , Merghoub Taha , Chaft Jamie E. , Reuss Joshua E. , Tam Ada J. , Blosser Richard L. , Abu-Akeel Mohsen , Sidhom John-William , Zhao Ni , Ha Jinny S. , Jones David R. , Marrone Kristen A. , Naidoo Jarushka , Gabrielson Edward , Taube Janis M. , Velculescu Victor E. , Brahmer Julie R. , Housseau Franck , Hellmann Matthew D. , Forde Patrick M. , Pardoll Drew M. , Ji Hongkai , Smith Kellie N.
Published: April 2023

Clinical and genomic data for patients included in our study
Table S5 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Summary of the multivariate Cox proportional hazards model for both mCRC (FOLFOX or FOLFIRI) and PDAC (FOLFIRINOX or nab-paclitaxel/gemcitabine) RWE with respect to overall
Supplementary Table S2 from Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer
Authors: Vidula Neelima , Niemierko Andrzej , Malvarosa Giuliana , Yuen Megan , Lennerz Jochen , Iafrate A. John , Wander Seth A. , Spring Laura , Juric Dejan , Isakoff Steven , Younger Jerry , Moy Beverly , Ellisen Leif W. , Bardia Aditya
Published: April 2023

Supplemental Table S2. Characteristics of patients who underwent both cfDNA and tumor tissue genotyping testing.
Table S3 from Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer
Authors: Abraham Jim P. , Magee Daniel , Cremolini Chiara , Antoniotti Carlotta , Halbert David D. , Xiu Joanne , Stafford Phillip , Berry Donald A. , Oberley Matthew J. , Shields Anthony F. , Marshall John L. , Salem Mohamed E. , Falcone Alfredo , Grothey Axel , Hall Michael J. , Venook Alan P. , Lenz Heinz-Josef , Helmstetter Anthony , Korn W. Michael , Spetzler David B.
Published: April 2023

Demographics of the cases used in the EC/GEJC RWE testing set.
Supplementary Materials III: Supplementary Figures S41-70 from Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model
Authors: Andreassen Maren M. Sjaastad , Rodríguez-Soto Ana E. , Conlin Christopher C. , Vidić Igor , Seibert Tyler M. , Wallace Anne M. , Zare Somaye , Kuperman Joshua , Abudu Boya , Ahn Grace S. , Hahn Michael , Jerome Neil P. , Østlie Agnes , Bathen Tone F. , Ojeda-Fournier Haydee , Goa Pål Erik , Rakow-Penner Rebecca , Dale Anders M.
Published: April 2023

Probability density colormaps for the three-component model given C1 and C2 for all voxels per patient for (A.) cancer (cancer ROI) and (B.) healthy breast tissue (control ROI).
Supplementary Materials I: Supplementary Tables S1-3 from Discrimination of Breast Cancer from Healthy Breast Tissue Using a Three-component Diffusion-weighted MRI Model
Authors: Andreassen Maren M. Sjaastad , Rodríguez-Soto Ana E. , Conlin Christopher C. , Vidić Igor , Seibert Tyler M. , Wallace Anne M. , Zare Somaye , Kuperman Joshua , Abudu Boya , Ahn Grace S. , Hahn Michael , Jerome Neil P. , Østlie Agnes , Bathen Tone F. , Ojeda-Fournier Haydee , Goa Pål Erik , Rakow-Penner Rebecca , Dale Anders M.
Published: April 2023

Mean (95% CI) for all performance measures the U.S. dataset (Supplementary Table S1) and European dataset (Supplementary Table S2). Median (interquartile range) for average signal of the cancer and control regions of interests (ROIs) for both datasets combined (Supplementary Table S3).
Supplementary Data from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Bioanalysis section and supplementary tables
Figure S4 from Exposure–Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing
Authors: Campagne Olivia , Zhong Bo , Nair Sreenath , Lin Tong , Huang Jie , Onar-Thomas Arzu , Robinson Giles , Gajjar Amar , Stewart Clinton F.
Published: April 2023

Visual predictive checks of the PK base model
Supplementary Data from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Suppl Fig Legends
Supplementary Methods from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Methods not essential to the main conclusions but important for critical review of methods used for this work
Supplementary Figure S8 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S8. SX-682 does not directly alter MOC2 cells in vitro
Suppl Fig S2B from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Supplementary Figure S2. Summary of observed alterations in CDK12 (B)
Supplementary Figure S6 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Authors: Greene Sarah , Robbins Yvette , Mydlarz Wojciech K. , Huynh Angel P. , Schmitt Nicole C. , Friedman Jay , Horn Lucas A. , Palena Claudia , Schlom Jeffrey , Maeda Dean Y. , Zebala John A. , Clavijo Paul E. , Allen Clint
Published: April 2023

Supplemental Figure S6. SX-682 treatment does not enhance MOC2 tumor T cell infiltration
Suppl Fig S2A from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Supplementary Figure S2. Summary of observed alterations in ATM (A)
Suppl Fig S1 from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Authors: Abida Wassim , Campbell David , Patnaik Akash , Shapiro Jeremy D. , Sautois Brieuc , Vogelzang Nicholas J. , Voog Eric G. , Bryce Alan H. , McDermott Ray , Ricci Francesco , Rowe Julie , Zhang Jingsong , Piulats Josep Maria , Fizazi Karim , Merseburger Axel S. , Higano Celestia S. , Krieger Laurence E. , Ryan Charles J. , Feng Felix Y. , Simmons Andrew D. , Loehr Andrea , Despain Darrin , Dowson Melanie , Green Foad , Watkins Simon P. , Golsorkhi Tony , Chowdhury Simon
Published: April 2023

Supplementary Figure S1. Incidence of gene alteration types for patients from TRITON2 with non-BRCA DDR gene alterations.
Supplementary Figure 4B from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Authors: Armstrong Andrew J. , Nixon Andrew B. , Carmack Andrea , Yang Qian , Eisen Tim , Stadler Walter M. , Jones Robert J. , Garcia Jorge A. , Vaishampayan Ulka N. , Picus Joel , Hawkins Robert E. , Hainsworth John D. , Kollmannsberger Christian K. , Logan Theodore F. , Puzanov Igor , Pickering Lisa M. , Ryan Christopher W. , Protheroe Andrew , George Daniel J. , Halabi Susan
Published: April 2023

Supplementary Figure 4B Kaplan-Meier OS curves by treatment and dichotomized angiokines groups for following angiokines: TGFb-R3, HGF, TSP-2, OPN, IL-6, SDF-1, Ang-2, ICAM-1, TGF-b2, TIMP-1, BMP-9, PDGF-BB, VCAM-1, PDGF-AA, VEGF-D, TGF-b1, VEGF-R1, HER-3, VEGF, PlGF, CD-73, VEGF-R3, and VEGF-R2
Supplementary Figure 2 from Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma
Authors: Armstrong Andrew J. , Nixon Andrew B. , Carmack Andrea , Yang Qian , Eisen Tim , Stadler Walter M. , Jones Robert J. , Garcia Jorge A. , Vaishampayan Ulka N. , Picus Joel , Hawkins Robert E. , Hainsworth John D. , Kollmannsberger Christian K. , Logan Theodore F. , Puzanov Igor , Pickering Lisa M. , Ryan Christopher W. , Protheroe Andrew , George Daniel J. , Halabi Susan
Published: April 2023

Supplementary Figure 2. Kaplan-Meier PFS curves by dichotomized angiokines: CD-73, BMP-9, VEGF-R1, PDGF-BB, VEGF, IL-6, VCAM-1, OPN, HGF, PDGF-AA, TGFb-R3, TGF-b1, VEGF-R3, and TGF-b2
Supplementary Figure 4 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

Supplementary FIgure 4 AMG 757 demonstrated antitumor activity in the WM266-4 melanoma xenograft model.
Supplementary Figure 2 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Authors: Giffin Michael J. , Cooke Keegan , Lobenhofer Edward K. , Estrada Juan , Zhan Jinghui , Deegen Petra , Thomas Melissa , Murawsky Christopher M. , Werner Jonathan , Liu Siyuan , Lee Fei , Homann Oliver , Friedrich Matthias , Pearson Joshua T. , Raum Tobias , Yang Yajing , Caenepeel Sean , Stevens Jennitte , Beltran Pedro J. , Canon Jude , Coxon Angela , Bailis Julie M. , Hughes Paul E.
Published: April 2023

Supplementary Figure 2 Representative photomicrographs of DLL3 immunostaining (brown color) in normal human tissues using immunohistochemistry.
Table S5 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S5
Supplemental Table 2 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

This table describes the dose exposure in this study.
Supplemental Table 1 from Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Authors: Hellmann Matthew D. , Bivi Nicoletta , Calderon Boris , Shimizu Toshio , Delafontaine Brant , Liu Zhuqing Tina , Szpurka Anna M. , Copeland Victoria , Hodi F. Stephen , Rottey Sylvie , Aftimos Philippe , Piao Yongzhe , Gandhi Leena , Galvao Violeta Regnier , Leow Ching Ching , Doi Toshihiko
Published: April 2023

This table contains the baseline patient demographics and disease characteristics.
Table S1 from Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer
Authors: Akcakanat Argun , Zheng Xiaofeng , Cruz Pico Christian X. , Kim Tae-Beom , Chen Ken , Korkut Anil , Sahin Aysegul , Holla Vijaykumar , Tarco Emily , Singh Gopal , Damodaran Senthil , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

Table S1
Supplementary Table 2 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Authors: Clifton G. Travis , Hale Diane , Vreeland Timothy J. , Hickerson Annelies T. , Litton Jennifer K. , Alatrash Gheath , Murthy Rashmi K. , Qiao Na , Philips Anne V. , Lukas Jason J. , Holmes Jarrod P. , Peoples George E. , Mittendorf Elizabeth A.
Published: April 2023

Clinicopathologic characteristics of randomized triple-negative breast cancer patients
Supplementary File description from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary File Figure legends
Supplementary Table 1 from Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
Authors: Clifton G. Travis , Hale Diane , Vreeland Timothy J. , Hickerson Annelies T. , Litton Jennifer K. , Alatrash Gheath , Murthy Rashmi K. , Qiao Na , Philips Anne V. , Lukas Jason J. , Holmes Jarrod P. , Peoples George E. , Mittendorf Elizabeth A.
Published: April 2023

Adverse Events
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Figure 2. R-based gating setting and detection of TERT Promoter Mutation in Plasma of Discovery, Validation and Multi-Institution Cohorts
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Figure 4. Correlations between (a) progression free survival, (b) overall survival, (c) tumor grade, (d) contrast enhancement, (e) type of TERT mutation, (f) tumor volume, (g) duration of disease, (h) age. Contingency tables are provided for (i) Discovery Sample Set 1 (j) Discovery Sample Set 2 (k) MultiInstitution Validation Cohort (l) Overall Combined Cohort. (m) 4 replicates of 4 uL of cfDNA from matched CSF samples (n=4; n=3 TERT mutant and n=1 WT) was used as input for absolute quantification of TERT mutant and wildtype copies. MAF is calculated using the formula described in Methods. Copies/mL for plasma samples are plotted against Study ID, classified by SNapSHOT/Pathology as floating bars, with line at the mean copies/mL. (n) Contingency table for matched CSF plasma.
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Table 2
Supplementary Data from TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas
Authors: Muralidharan Koushik , Yekula Anudeep , Small Julia L. , Rosh Zachary S. , Kang Keiko M. , Wang Lan , Lau Spencer , Zhang Hui , Lee Hakho , Bettegowda Chetan , Chicoine Michael R. , Kalkanis Steven N. , Shankar Ganesh M. , Nahed Brian V. , Curry William T. , Jones Pamela S. , Cahill Daniel P. , Balaj Leonora , Carter Bob S.
Published: April 2023

Supplementary Table 1
Supplementary Data from Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response
Authors: Karzai Fatima , Walker Stephanie M. , Wilkinson Scott , Madan Ravi A. , Shih Joanna H. , Merino Maria J. , Harmon Stephanie A. , VanderWeele David J. , Cordes Lisa M. , Carrabba Nicole V. , Bright John R. , Terrigino Nicolas T. , Chun Guinevere , Bilusic Marijo , Couvillon Anna , Hankin Amy , Williams Monique N. , Lis Rosina T. , Ye Huihui , Choyke Peter L. , Gulley James L. , Sowalsky Adam G. , Turkbey Baris , Pinto Peter A. , Dahut William L.
Published: April 2023

Contains supplementary methods and 3 supplementary tables.
Supplementary Tables from Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
Authors: Lin Jessica J. , Choudhury Noura J. , Yoda Satoshi , Zhu Viola W. , Johnson Ted W. , Sakhtemani Ramin , Dagogo-Jack Ibiayi , Digumarthy Subba R. , Lee Charlotte , Do Andrew , Peterson Jennifer , Prutisto-Chang Kylie , Malik Wafa , Hubbeling Harper G. , Langenbucher Adam , Schoenfeld Adam J. , Falcon Christina J. , Temel Jennifer S. , Sequist Lecia V. , Yeap Beow Y. , Lennerz Jochen K. , Shaw Alice T. , Lawrence Michael S. , Ou Sai-Hong Ignatius , Hata Aaron N. , Drilon Alexander , Gainor Justin F.
Published: April 2023

Supplementary Tables 1-2
Supplement from Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
Authors: Lin Jessica J. , Choudhury Noura J. , Yoda Satoshi , Zhu Viola W. , Johnson Ted W. , Sakhtemani Ramin , Dagogo-Jack Ibiayi , Digumarthy Subba R. , Lee Charlotte , Do Andrew , Peterson Jennifer , Prutisto-Chang Kylie , Malik Wafa , Hubbeling Harper G. , Langenbucher Adam , Schoenfeld Adam J. , Falcon Christina J. , Temel Jennifer S. , Sequist Lecia V. , Yeap Beow Y. , Lennerz Jochen K. , Shaw Alice T. , Lawrence Michael S. , Ou Sai-Hong Ignatius , Hata Aaron N. , Drilon Alexander , Gainor Justin F.
Published: April 2023

Supplementary methods, figure legends
Supplementary Data from Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis
Authors: Nassiri Farshad , Taslimi Shervin , Wang Justin Z. , Badhiwala Jetan H. , Dalcourt Tatyana , Ijad Nazanin , Pirouzmand Neda , Almenawer Saleh , Stupp Roger , Zadeh Gelareh
Published: April 2023

Supplementary Table 1. Additional baseline characteristics of all included studies (randomized and non-randomized). Supplementary Table 2. Cochrane Collaboration tool for assessing risk of bias in randomized trials. Supplementary Table 3. Newcastle Ottawa Quality Assessment Scale for cohort studies Supplemental Table 4. Results of the network meta-analysis including RCT only split by direct and indirect evidence and assessment of consistency between direct and indirect estimates Supplemental Table 5. Results of the network meta-analysis including non-randomized trials split by direct and indirect evidence and assessment of consistency between direct and indirect estimates Supplemental Table 6. Results of the network meta-analysis including trials adjusting for MGMT methylation promoter status split by direct and indirect evidence and assessment of consistency between direct and indirect estimates Supplemental Table 7. Quantification of heterogeneity and tests of heterogeneity (within designs) and inconsistency (between designs) for secondary efficacy outcomes
Supplementary Table 3 from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer
Authors: Keenan Tanya E. , Li Tianyu , Vallius Tuulia , Guerriero Jennifer L. , Tayob Nabihah , Kochupurakkal Bose , Davis Janae , Pastorello Ricardo , Tahara Rie K. , Anderson Leilani , Conway Jake , He Meng X. , Shannon Erin , Godin Robert E. , Sorger Peter K. , D'Andrea Alan , Overmoyer Beth , Winer Eric P. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Shapiro Geoffrey I. , Tolaney Sara M.
Published: April 2023

Supplementary Table 3
Supplementary Table 2 from Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Authors: Schoenfeld Adam J. , Chan Joseph M. , Kubota Daisuke , Sato Hiroki , Rizvi Hira , Daneshbod Yahya , Chang Jason C. , Paik Paul K. , Offin Michael , Arcila Maria E. , Davare Monika A. , Shinde Ujwal , Pe'er Dana , Rekhtman Natasha , Kris Mark G. , Somwar Romel , Riely Gregory J. , Ladanyi Marc , Yu Helena A.
Published: April 2023

Supplemental Table 2. Primer sequences
Supplementary Data from Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
Authors: Tolaney Sara M. , Im Young-Hyuck , Calvo Emiliano , Lu Yen-Shen , Hamilton Erika , Forero-Torres Andres , Bachelot Thomas , Maur Michela , Fasolo Angelica , Tiedt Ralph , Nardi Lisa , Stammberger Uz , Abdelhady Ahmed M. , Ruan Shiling , Lee Soo Chin
Published: April 2023

SUPPLEMENTARY APPENDIX TABLES
Table S1 from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Authors: Awasthi Shivanshu , Berglund Anders , Abraham-Miranda Julieta , Rounbehler Robert J. , Kensler Kevin , Serna Amparo , Vidal Adriana , You Sungyong , Freeman Michael R. , Davicioni Elai , Liu Yang , Karnes R. Jeffrey , Klein Eric A. , Den Robert B. , Trock Bruce J. , Campbell Joshua D. , Einstein David J. , Gupta Raavi , Balk Steven , Lal Priti , Park Jong Y. , Cleveland John L. , Rebbeck Timothy R. , Freedland Stephen J. , Yamoah Kosj
Published: April 2023

Table S1
Figure S2 from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Authors: Awasthi Shivanshu , Berglund Anders , Abraham-Miranda Julieta , Rounbehler Robert J. , Kensler Kevin , Serna Amparo , Vidal Adriana , You Sungyong , Freeman Michael R. , Davicioni Elai , Liu Yang , Karnes R. Jeffrey , Klein Eric A. , Den Robert B. , Trock Bruce J. , Campbell Joshua D. , Einstein David J. , Gupta Raavi , Balk Steven , Lal Priti , Park Jong Y. , Cleveland John L. , Rebbeck Timothy R. , Freedland Stephen J. , Yamoah Kosj
Published: April 2023

Correlation of A. Post-operative radiation therapy outcomes score (PORTOS), B. Radiation sensitivity index (RSI), C. CD4+, and D. Hallmark interferon (IFN)-gamma expression with hallmark DNA repair in validation DVAHS set.
Figure S1 from Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer
Authors: Awasthi Shivanshu , Berglund Anders , Abraham-Miranda Julieta , Rounbehler Robert J. , Kensler Kevin , Serna Amparo , Vidal Adriana , You Sungyong , Freeman Michael R. , Davicioni Elai , Liu Yang , Karnes R. Jeffrey , Klein Eric A. , Den Robert B. , Trock Bruce J. , Campbell Joshua D. , Einstein David J. , Gupta Raavi , Balk Steven , Lal Priti , Park Jong Y. , Cleveland John L. , Rebbeck Timothy R. , Freedland Stephen J. , Yamoah Kosj
Published: April 2023

Differences in genomic signatures within AAM and EAM in discovery set. For DVAHS validation only significance value is shown. For comparison, all the genomic signatures were uniformly scaled to positive values by adding a constant integer.
Supplementary Figures from Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer
Authors: Wolfe Adam R. , Robb Ryan , Hegazi Ahmad , Abushahin Laith , Yang Linlin , Shyu Duan-Liang , Trevino Jose G. , Cruz-Monserrate Zobeida , Jacob John R. , Palanichamy Kamalakannan , Chakravarti Arnab , Williams Terence M.
Published: April 2023

Supplementary Figures
Figure S1 from Everolimus Inhibits the Progression of Ductal Carcinoma In Situ to Invasive Breast Cancer Via Downregulation of MMP9 Expression
Authors: Chen Guang , Ding Xiao-Fei , Pressley Kyle , Bouamar Hakim , Wang Bingzhi , Zheng Guixi , Broome Larry E. , Nazarullah Alia , Brenner Andrew J. , Kaklamani Virginia , Jatoi Ismail , Sun Lu-Zhe
Published: April 2023

mTOR inhibition decreases MMP9 expression. A, Everolimus treatment for 24 hours did not reduced MMP2 protein levels in SUM225 cells. B, C and D figures were the MMP-9 IHC quantification data measuring average optical density using ImageJ d 1.47 software. B, one-week Everolimus treatments at 2 mg/kg/day significantly decreased MMP9 protein levels in the mammary gland of MMTV/neu mice (n=3). C, one-week-Everolimus treatments at 2 mg/kg decreased MMP9 protein levels in the mammary gland of SUM225-MIND mouse mammary tissues detected by IHC (n=4). D, one-week-rapamycin treatments at 2 mg/day reduced MMP9 protein levels in mammary glands of DCIS patients detected by IHC. **p<0.01 and * p<0.05 represents the comparison between control vehicle and everolimus treatment groups or pre-treatment and post-treatment group, respectively, t-test.
eTable2 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Univariate and multivariate analysis of PRKDC and TP53 loss with progression-free and overall survival following immune checkpoint-inhibitor-based therapies
eTable1 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Authors: Barroso-Sousa Romualdo , Keenan Tanya E. , Pernas Sonia , Exman Pedro , Jain Esha , Garrido-Castro Ana C. , Hughes Melissa , Bychkovsky Brittany , Umeton Renato , Files Janet L. , Lindeman Neal I. , MacConaill Laura E. , Hodi F. Stephen , Krop Ian E. , Dillon Deborah , Winer Eric P. , Wagle Nikhil , Lin Nancy U. , Mittendorf Elizabeth A. , Van Allen Eliezer M. , Tolaney Sara M.
Published: April 2023

Baseline characteristics for PD-L1 known cohort
Figure S2 from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Authors: Schoenfeld Adam J. , Bandlamudi Chai , Lavery Jessica A. , Montecalvo Joseph , Namakydoust Azadeh , Rizvi Hira , Egger Jacklynn , Concepcion Carla P. , Paul Sonal , Arcila Maria E. , Daneshbod Yahya , Chang Jason , Sauter Jennifer L. , Beras Amanda , Ladanyi Marc , Jacks Tyler , Rudin Charles M. , Taylor Barry S. , Donoghue Mark T.A. , Heller Glenn , Hellmann Matthew D. , Rekhtman Natasha , Riely Gregory J.
Published: April 2023

Overall survival by combination of STK11, KEAP1, and SMARCA4 alteration status.
Figure S1 from The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer
Authors: Schoenfeld Adam J. , Bandlamudi Chai , Lavery Jessica A. , Montecalvo Joseph , Namakydoust Azadeh , Rizvi Hira , Egger Jacklynn , Concepcion Carla P. , Paul Sonal , Arcila Maria E. , Daneshbod Yahya , Chang Jason , Sauter Jennifer L. , Beras Amanda , Ladanyi Marc , Jacks Tyler , Rudin Charles M. , Taylor Barry S. , Donoghue Mark T.A. , Heller Glenn , Hellmann Matthew D. , Rekhtman Natasha , Riely Gregory J.
Published: April 2023

Populations analyzed in genomic and clinical analyses.
Supplementary Data from Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
Authors: Molloy Mary Ellen , Austin Richard J. , Lemon Bryan D. , Aaron Wade H. , Ganti Vaishnavi , Jones Adrie , Jones Susan D. , Strobel Kathryn L. , Patnaik Purbasa , Sexton Kenneth , Tatalick Laurie , Yu Timothy Z. , Baeuerle Patrick A. , Law Che-Leung , Wesche Holger
Published: April 2023

Supplementary data
Supplementary Figure S3 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S3. The waterfall plots of the best percentage change in the tumor burden from baseline evaluation in patients treated with CAPTEM (A) and FOLFIRI (B).
Supplementary Figure S2 from Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer
Authors: Pietrantonio Filippo , Lobefaro Riccardo , Antista Maria , Lonardi Sara , Raimondi Alessandra , Morano Federica , Mosconi Stefania , Rimassa Lorenza , Murgioni Sabina , Sartore-Bianchi Andrea , Tomasello Gianluca , Longarini Raffaella , Farina Gabriella , Petrelli Fausto , Gori Stefania , Randon Giovanni , Corallo Salvatore , Pagani Filippo , Guarini Vincenzo , Palermo Federica , Martinetti Antonia , Macagno Marco , Barault Ludovic , Perrone Federica , Tamborini Elena , Milione Massimo , Di Nicolantonio Federica , Di Maio Massimo , Fucà Giovanni , Di Bartolomeo Maria , de Braud Filippo
Published: April 2023

Supplementary Figure S2. Forest plots of overall survival by patient subgroups within the intention-to-treat population.
Supplementary Figure S4 from The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Authors: Deegen Petra , Thomas Oliver , Nolan-Stevaux Olivier , Li Shyun , Wahl Joachim , Bogner Pamela , Aeffner Famke , Friedrich Matthias , Liao Michael Z. , Matthes Katja , Rau Doris , Rattel Benno , Raum Tobias , Kufer Peter , Coxon Angela , Bailis Julie M.
Published: April 2023

Figure S4. Faster clearance of AMG 160 in the NSG B2M mouse strain.
Figure S7 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Concordance between patient-matched tissue and liquid biopsies.
Figure S10 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Authors: Tukachinsky Hanna , Madison Russell W. , Chung Jon H. , Gjoerup Ole V. , Severson Eric A. , Dennis Lucas , Fendler Bernard J. , Morley Samantha , Zhong Lei , Graf Ryon P. , Ross Jeffrey S. , Alexander Brian M. , Abida Wassim , Chowdhury Simon , Ryan Charles J. , Fizazi Karim , Golsorkhi Tony , Watkins Simon P. , Simmons Andrew , Loehr Andrea , Venstrom Jeffrey M. , Oxnard Geoffrey R.
Published: April 2023

Distribution of the ratio of variant allele frequency to ctDNA fraction of mutations and rearrangements in the AR gene.
Supplemental Figure S1 from Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)
Authors: Xu Wenxin , Puligandla Mäneka , Halbert Brian , Haas Naomi B. , Flaherty Keith T. , Uzzo Robert G. , Dutcher Janice P. , DiPaola Robert S. , Sabbisetti Venkata , Bhatt Rupal S.
Published: April 2023

Distribution of baseline KIM-1 values
Table S1 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Commercial antibodies
Figure S7 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Binding of 4-1BBN/CEGFR to cell surface expressed hu4-1BB and huEGFR.
Figure S12 from An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity
Authors: Compte Marta , Harwood Seandean L. , Erce-Llamazares Ainhoa , Tapia-Galisteo Antonio , Romero Eduardo , Ferrer Irene , Garrido-Martin Eva M. , Enguita Ana B. , Ochoa Maria C. , Blanco Belén , Oteo Marta , Merino Nekane , Nehme-Álvarez Daniel , Hangiu Oana , Domínguez-Alonso Carmen , Zonca Manuela , Ramírez-Fernández Angel , Blanco Francisco J. , Morcillo Miguel A. , Muñoz Ines G. , Melero Ignacio , Rodriguez-Peralto José L. , Paz-Ares Luis , Sanz Laura , Alvarez-Vallina Luis
Published: April 2023

Structural and functional characterization of 4-1BBN/CEGFR after conjugation with p-SCN-Bn-deferoxamine (Df).
Figure S2 from A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Authors: Santich Brian H. , Cheal Sarah M. , Ahmed Mahiuddin , McDevitt Michael R. , Ouerfelli Ouathek , Yang Guangbin , Veach Darren R. , Fung Edward K. , Patel Mitesh , Burnes Vargas Daniela , Malik Aiza A. , Guo Hong-Fen , Zanzonico Pat B. , Monette Sebastien , Michel Adam O. , Rudin Charles M. , Larson Steven M. , Cheung Nai K.
Published: April 2023

summary of toxicity data from 177Lu SADA-PRIT experiment against a neuroblastoma cell line
Figure S1 from A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
Authors: Santich Brian H. , Cheal Sarah M. , Ahmed Mahiuddin , McDevitt Michael R. , Ouerfelli Ouathek , Yang Guangbin , Veach Darren R. , Fung Edward K. , Patel Mitesh , Burnes Vargas Daniela , Malik Aiza A. , Guo Hong-Fen , Zanzonico Pat B. , Monette Sebastien , Michel Adam O. , Rudin Charles M. , Larson Steven M. , Cheung Nai K.
Published: April 2023

Summary of immunogenicity experiment.
Supplemental Table 2 from Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers
Authors: Tsang Erica S. , Grisdale Cameron J. , Pleasance Erin , Topham James T. , Mungall Karen , Reisle Caralyn , Choo Caleb , Carreira Marcus , Bowlby Reanne , Karasinska Joanna M. , MacMillan Daniel , Williamson Laura M. , Chuah Eric , Moore Richard A. , Mungall Andrew J. , Zhao Yongjun , Tessier-Cloutier Basile , Ng Tony , Sun Sophie , Lim Howard J. , Schaeffer David F. , Renouf Daniel J. , Yip Stephen , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Loree Jonathan M.
Published: April 2023

Supplemental Table 2
Supplemental Table 1 from Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers
Authors: Tsang Erica S. , Grisdale Cameron J. , Pleasance Erin , Topham James T. , Mungall Karen , Reisle Caralyn , Choo Caleb , Carreira Marcus , Bowlby Reanne , Karasinska Joanna M. , MacMillan Daniel , Williamson Laura M. , Chuah Eric , Moore Richard A. , Mungall Andrew J. , Zhao Yongjun , Tessier-Cloutier Basile , Ng Tony , Sun Sophie , Lim Howard J. , Schaeffer David F. , Renouf Daniel J. , Yip Stephen , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Loree Jonathan M.
Published: April 2023

Supplemental Table 1
Figure S1 from Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors
Authors: Spicer James , Marabelle Aurélien , Baurain Jean-Francois , Jebsen Nina Louise , Jøssang Dag Erik , Awada Ahmad , Kristeleit Rebecca , Loirat Delphine , Lazaridis George , Jungels Christiane , Brunsvig Paal , Nicolaisen Berit , Saunders Andrew , Patel Hamina , Galon Jérôme , Hermitte Fabienne , Camilio Ketil André , Mauseth Brynjar , Sundvold Vibeke , Sveinbjørnsson Baldur , Rekdal Øystein
Published: April 2023

Figure S1 shows analysis of the abundance of unique T-cell clones in blood at baseline compared to after treatment.
Supplementary Materials and Methods from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

Additional supporting information for methods outlined in main manuscript
Supplementary Figure 8 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

Densitometry analysis for Figure 6D/E
Supplementary Figures from Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Authors: Jhaveri Komal , Chang Matthew T. , Juric Dejan , Saura Cristina , Gambardella Valentina , Melnyk Anton , Patel Manish R. , Ribrag Vincent , Ma Cynthia X. , Aljumaily Raid , Bedard Philippe L. , Sachdev Jasgit C. , Dunn Lara , Won Helen , Bond John , Jones Surai , Savage Heidi M. , Scaltriti Maurizio , Wilson Timothy R. , Wei Michael C. , Hyman David M.
Published: April 2023

Supplementary Figures
Supplementary Figure S3 from A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma
Authors: Kalbasi Anusha , Kamrava Mitchell , Chu Fang-I , Telesca Donatello , Van Dams Ritchell , Yang Yingli , Ruan Dan , Nelson Scott D. , Dry Sarah M. , Hernandez Jackie , Chmielowski Bartosz , Singh Arun S. , Bukata Susan V. , Bernthal Nicholas M. , Steinberg Michael L. , Weidhaas Joanne B. , Eilber Fritz C.
Published: April 2023

Figure S3 - Distribution of soft tissue sarcoma histologic subtypes among patients enrolled on the five-day neoadjuvant RT phase 2 study
Supplementary Figure 2 from Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer
Authors: Collins Denis M. , Madden Stephen F. , Gaynor Nicola , AlSultan Dalal , Le Gal Marion , Eustace Alex J. , Gately Kathy A. , Hughes Clare , Davies Anthony M. , Mahgoub Thamir , Ballot Jo , Toomey Sinead , O'Connor Darran P. , Gallagher William M. , Holmes Frankie A. , Espina Virginia , Liotta Lance , Hennessy Bryan T. , O'Byrne Kenneth J. , Hasmann Max , Bossenmaier Birgit , O'Donovan Norma , Crown John
Published: April 2023

Flow cytometry control scatter plots for trastuzumab-488 and pertuzumab-550